NASDAQ:EYPT

EyePoint Pharmaceuticals - EYPT Stock Forecast, Price & News

$3.03

-0.02 (-0.66%)

(As of 12/8/2022 12:00 AM ET)

Add

Compare

Today's Range: $2.99
▼
$3.20
50-Day Range: $3.03
▼
$7.91
52-Week Range: $2.97
▼
$15.50

Volume: 95,339 shs
Average Volume: 164,101 shs
Market Capitalization: $103.27 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $23.00

EyePoint Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 978.1% Upside
$32.67 Price Target
Short Interest: Bearish
7.11% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.54
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($2.15) to ($2.74) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

525th out of 1,022 stocks

Analytical Instruments Industry

16th out of 28 stocks

3.5

Analyst's Opinion

Consensus Rating
EyePoint Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $32.67, EyePoint Pharmaceuticals has a forecasted upside of 978.1% from its current price of $3.03.
Amount of Analyst Coverage
EyePoint Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
7.11% of the float of EyePoint Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
EyePoint Pharmaceuticals has a short interest ratio ("days to cover") of 14.1, which indicates bearish sentiment.
Change versus previous month
Short interest in EyePoint Pharmaceuticals has recently decreased by 9.14%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
EyePoint Pharmaceuticals does not currently pay a dividend.
Dividend Growth
EyePoint Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for EYPT.

2.5

News and Social Media Coverage

News Sentiment
EyePoint Pharmaceuticals has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for EyePoint Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
5 people have searched for EYPT on MarketBeat in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, EyePoint Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
11.88% of the stock of EyePoint Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
88.65% of the stock of EyePoint Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for EyePoint Pharmaceuticals are expected to decrease in the coming year, from ($2.15) to ($2.74) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of EyePoint Pharmaceuticals is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of EyePoint Pharmaceuticals is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
EyePoint Pharmaceuticals has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Receive EYPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EYPT Stock News Headlines

December 3, 2022 | wsj.com

Bragar Eagel & Squire, P.C. Is Investigating GrafTech, BRP, Cantaloupe, and EyePoint and Encourages Investors to Contact the Firm

December 1, 2022 | finance.yahoo.com

Investors in EyePoint Pharmaceuticals (NASDAQ:EYPT) have unfortunately lost 79% over the last year

November 2, 2022 | msn.com

EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates

November 2, 2022 | finance.yahoo.com

EyePoint Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Developments

October 26, 2022 | finance.yahoo.com

EyePoint Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 2, 2022

October 19, 2022 | marketwatch.com

Bragar Eagel & Squire, P.C. Is Investigating EyePoint, Spectrum, F45, and PROG and Encourages Investors to Contact the Firm

October 11, 2022 | seekingalpha.com

EYPT EyePoint Pharmaceuticals, Inc.

October 7, 2022 | finance.yahoo.com

Strength Seen in Provention Bio, Inc. (PRVB): Can Its 25.7% Jump Turn into More Strength?

October 4, 2022 | marketwatch.com

EyePoint Investor Alert

September 30, 2022 | fool.com

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT)

September 29, 2022 | finance.yahoo.com

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Clinical Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathy

September 1, 2022 | apnews.com

EyePoint Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm

August 31, 2022 | benzinga.com

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in EyePoint Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

August 31, 2022 | benzinga.com

EyePoint Pharmaceuticals Shareholder News: Johnson Fistel Encourages EYPT Shareholders with Losses to Contact the Firm Regarding Investigation

August 30, 2022 | apnews.com

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in EyePoint Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

August 3, 2022 | seekingalpha.com

EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q2 2022 Results - Earnings Call Transcript

August 3, 2022 | finance.yahoo.com

EyePoint Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Developments

August 2, 2022 | msn.com

Earnings Preview For EyePoint Pharmaceuticals

August 1, 2022 | finance.yahoo.com

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Maintenance Treatment of Wet AMD

July 27, 2022 | finance.yahoo.com

EyePoint Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022

July 18, 2022 | finance.yahoo.com

EyePoint Pharmaceuticals Investor Day to Highlight EYP-1901 and Durasert® Technology Developments and Provide a Financial Update

July 15, 2022 | nasdaq.com

EyePoint: 12-month Data From DAVIO Trial Reinforces Safety, Efficacy For EYP-1901

July 15, 2022 | finance.yahoo.com

EyePoint Pharmaceuticals Announces Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD

July 11, 2022 | finance.yahoo.com

EyePoint Pharmaceuticals Appoints Karen Zaderej to Board of Directors

July 11, 2022 | finance.yahoo.com

EyePoint Pharmaceuticals to Host Investor Day on July 18, 2022

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive EYPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EYPT Company Calendar

Last Earnings: 11/02/2022
Today: 12/09/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/02/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Analytical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:EYPT
CUSIP: N/A
CIK: 1314102
Web: eyepointpharma.com
Phone: (617) 926-5000
Fax: 617-926-5050
Employees: 122
Year Founded: 1987

Price Target and Rating

Average Stock Price Forecast: $32.67
High Stock Price Forecast: $52.00
Low Stock Price Forecast: $21.00
Forecasted Upside/Downside: +659.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.16)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-58,420,000.00
Net Margins: -186.02%
Pretax Margin: -186.02%
Return on Equity: -48.00%
Return on Assets: -31.89%

Debt

Debt-to-Equity Ratio: 0.21
Current Ratio: 5.61
Quick Ratio: 5.50

Sales & Book Value

Annual Sales: $35.31 million
Price / Sales: 2.92
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.44 per share
Price / Book: 0.56

Miscellaneous

Outstanding Shares: 34,083,000
Free Float: 30,034,000
Market Cap: $103.27 million
Optionable: Optionable
Beta: 0.97

Social Links

Key Executives

Ms. Nancy S. Lurker (Age 65)
Pres, CEO & Director
Comp: $1.11M

Mr. George O. Elston (Age 57)
Chief Financial Officer
Comp: $743.86k

Dr. Jay S. Duker M.D. (Age 63)
Chief Operating Officer
Comp: $614.96k

Mr. David Scott Jones (Age 55)
Sr. VP & Chief Commercial Officer
Comp: $672.08k

Mr. Said Saim (Age 64)
Chief Technology Officer

Mr. Ron I. Honig Esq.
Chief Legal Officer & Company Sec.

Mr. Michael Pine (Age 46)
Chief Corp. Devel. & Strategy Officer

Ms. Jennifer Leonard
Chief People Officer & Sr. VP of IT

Dr. Dario A. Paggiarino (Age 65)
Sr. VP & Chief Medical Officer

Ms. Isabelle Lefebvre
Chief Regulatory Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EYPT Stock - Frequently Asked Questions

Should I buy or sell EyePoint Pharmaceuticals stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for EyePoint Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EYPT shares.
View EYPT analyst ratings or view top-rated stocks.
What is EyePoint Pharmaceuticals' stock price forecast for 2023?: 4 brokerages have issued 12 month price objectives for EyePoint Pharmaceuticals' stock. Their EYPT share price forecasts range from $21.00 to $52.00. On average, they expect the company's share price to reach $32.67 in the next twelve months. This suggests a possible upside of 978.1% from the stock's current price.
View analysts price targets for EYPT or view top-rated stocks among Wall Street analysts.
How have EYPT shares performed in 2022?: EyePoint Pharmaceuticals' stock was trading at $12.24 at the beginning of 2022. Since then, EYPT stock has decreased by 75.2% and is now trading at $3.03.
View the best growth stocks for 2022 here.
Are investors shorting EyePoint Pharmaceuticals?: EyePoint Pharmaceuticals saw a drop in short interest in November. As of November 15th, there was short interest totaling 1,790,000 shares, a drop of 9.1% from the October 31st total of 1,970,000 shares. Based on an average trading volume of 126,700 shares, the days-to-cover ratio is currently 14.1 days. Currently, 7.1% of the shares of the stock are sold short.
View EyePoint Pharmaceuticals' Short Interest.
When is EyePoint Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our EYPT earnings forecast.
How were EyePoint Pharmaceuticals' earnings last quarter?: EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) released its quarterly earnings results on Wednesday, November, 2nd. The company reported ($0.49) EPS for the quarter, beating analysts' consensus estimates of ($0.70) by $0.21. The company earned $10.01 million during the quarter, compared to analyst estimates of $10.06 million. EyePoint Pharmaceuticals had a negative trailing twelve-month return on equity of 48.00% and a negative net margin of 186.02%.

When did EyePoint Pharmaceuticals' stock split?: EyePoint Pharmaceuticals's stock reverse split before market open on Wednesday, December 9th 2020. The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of EyePoint Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other EyePoint Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), Inovio Pharmaceuticals (INO), Verastem (VSTM), XOMA (XOMA), AcelRx Pharmaceuticals (ACRX), Catalyst Pharmaceuticals (CPRX), Progenics Pharmaceuticals (PGNX), Corbus Pharmaceuticals (CRBP) and Dynavax Technologies (DVAX).
What is EyePoint Pharmaceuticals' stock symbol?: EyePoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT."
Who are EyePoint Pharmaceuticals' major shareholders?: EyePoint Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.84%), Vanguard Group Inc. (4.10%), Verition Fund Management LLC (1.66%), Point72 Asset Management L.P. (1.44%), State Street Corp (1.27%) and Essex Investment Management Co. LLC (1.00%). Insiders that own company stock include George Elston and Nancy Lurker.
View institutional ownership trends.
How do I buy shares of EyePoint Pharmaceuticals?: Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is EyePoint Pharmaceuticals' stock price today?: One share of EYPT stock can currently be purchased for approximately $3.03.
How much money does EyePoint Pharmaceuticals make?: EyePoint Pharmaceuticals (NASDAQ:EYPT) has a market capitalization of $103.27 million and generates $35.31 million in revenue each year. The company earns $-58,420,000.00 in net income (profit) each year or ($2.16) on an earnings per share basis.
How many employees does EyePoint Pharmaceuticals have?: The company employs 122 workers across the globe.
How can I contact EyePoint Pharmaceuticals?: EyePoint Pharmaceuticals' mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The official website for the company is eyepointpharma.com. The company can be reached via phone at (617) 926-5000, via email at eyepoint@argotpartners.com, or via fax at 617-926-5050.

This page (NASDAQ:EYPT) was last updated on 12/9/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial